AV
Ashwani Verma
Executive
UBS analyst who estimates market impacts for pharmaceutical products.
Notable Quotes
"We believe it is unlikely that Auvelity will receive the black box warning typically associated with antipsychotics, given that it is neither molecularly an antipsychotic nor indicated for the treatment of psychosis."View Story →